FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC.
Cleary JM, et al. Among authors: graham c.
Cancer. 2019 Jul 1;125(13):2213-2221. doi: 10.1002/cncr.32029. Epub 2019 Mar 26.
Cancer. 2019.
PMID: 30913304
Free PMC article.
Clinical Trial.